Is biliary atresia an immune mediated disease? (Englisch)

in JOURNAL OF HEPATOLOGY ; 59 , 4 ; 648-650
JOURNAL OF HEPATOLOGY
Wie erhalte ich diesen Titel?
TIB vor Ort

Für Benutzerinnen und Benutzer auf dem LUH Campus überprüfen wir gerne den kostenfreien Bezug.

Anfrage Verfügbarkeit LUH

Dokumentinformationen

  • Titel:
    Is biliary atresia an immune mediated disease?
  • Autor / Urheber:
  • Zeitschrift / Reihe:
  • Band:
    59
  • Ausgabe:
    4
  • Seite:
    648-650
  • Verlag:
    Elsevier Science B.V., Amsterdam.
  • Erscheinungsjahr:
    2013
  • Format / Umfang:
    3 pages
  • ISSN:
  • Medientyp:
    Aufsatz (Zeitschrift)
  • Format:
    Print
  • Sprache:
    Englisch
  • Klassifikation:
    DDC:    616.3623

Inhaltsverzeichnis – Band 59, Ausgabe 4

Zeige alle Jahrgänge und Ausgaben

Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Nachweisen der enthaltenen Aufsätze. Die Anzeige der Jahrgänge kann aufgrund fehlender Aufsatznachweise unvollständig oder lückenhaft sein, obwohl die Zeitschrift komplett in der TIB verfügbar ist.

643
Focus
Shouval, D. | 2013
646
Does occult HBV infection have an impact on the evolution of chronic hepatitis C?
Zoulim, F. | 2013
648
Is biliary atresia an immune mediated disease?
Alvarez, Fernando | 2013
651
Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: A pilot study
Bladowska, Joanna / Zimny, Anna / Knysz, Brygida / Małyszczak, Krzysztof / Kołtowska, Anna / Szewczyk, Paweł / Gąsiorowski, Jacek / Furdal, Michał / Sąsiadek, Marek J. | 2013
658
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
Cammà, Calogero / Petta, Salvatore / Cabibbo, Giuseppe / Ruggeri, Matteo / Enea, Marco / Bruno, Raffaele / Capursi, Vincenza / Gasbarrini, Antonio / Alberti, Alfredo / Craxì, Antonio | 2013
667
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy
Ogawa, E. / Furusyo, N. / Nakamuta, M. / Kajiwara, E. / Nomura, H. / Dohmen, K. / Takahashi, K. / Satoh, T. / Azuma, K. / Kawano, A. | 2013
675
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
Poynard, T. / Moussalli, J. / Munteanu, M. / Thabut, D. / Lebray, P. / Rudler, M. / Ngo, Y. / Thibault, V. / Mkada, H. / Charlotte, F. | 2013
684
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy
Lavocat, F. / Dény, P. / Pichoud, C. / Al Hawajri, N. / Kitrinos, K. / Borroto-Esoda, K. / Zoulim, F. | 2013
696
Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C
Squadrito, Giovanni / Cacciola, Irene / Alibrandi, Angela / Pollicino, Teresa / Raimondo, Giovanni | 2013
701
Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes
Brownell, Jessica / Wagoner, Jessica / Lovelace, Erica S. / Thirstrup, Derek / Mohar, Isaac / Smith, Wesley / Giugliano, Silvia / Li, Kui / Crispe, I. Nicholas / Rosen, Hugo R. et al. | 2013
709
Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment
Seto, W. K. / Liu, K. / Wong, D. K. / Fung, J. / Huang, F. Y. / Hung, I. F. / Lai, C. L. / Yuen, M. F. | 2013
717
Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension
Berzigotti, A. / Reverter, E. / García-Criado, n. / Abraldes, J. G. / Cerini, F. / García-Pagán, J. C. / Bosch, J. | 2013
723
Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis
Lario, Margaret / Muñoz, Leticia / Ubeda, María / Borrero, María-José / Martínez, Javier / Monserrat, Jorge / Díaz, David / Álvarez-Mon, Melchor / Albillos, Agustín | 2013
731
Impaired liver regeneration in Ldlr−/− mice is associated with an altered hepatic profile of cytokines, growth factors, and lipids
Pauta, Montse / Rotllan, Noemi / Vales, Frances / Fernandez-Hernando, Ana / Allen, Ryan M. / Ford, David A. / Marí, Montserrat / Jiménez, Wladimiro / Baldán, Ángel / Morales-Ruiz, Manuel et al. | 2013
738
IFN-γ inhibits liver progenitor cell proliferation in HBV-infected patients and in 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-fed mice
Weng, Hong-lei / Feng, De-chun / Radaeva, Svetlana / Kong, Xiao-ni / Wang, Lei / Liu, Yan / Li, Qi / Shen, Hong / Gao, Yun-peng / Müllenbach, Roman et al. | 2013
746
Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing “stemness”-related markers
Kim, H. / Yoo, J. E. / Cho, J. Y. / Oh, B. K. / Yoon, Y. S. / Han, H. S. / Lee, H. S. / Jang, J. J. / Jeong, S. H. / Kim, J. W. | 2013
753
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma
Golfieri, Rita / Bilbao, Josè Ignacio / Carpanese, Livio / Cianni, Roberto / Gasparini, Daniele / Ezziddin, Samer / Paprottka, Philipp Marius / Fiore, Francesco / Cappelli, Alberta / Rodriguez, Macarena et al. | 2013
762
p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release
Yan, He-Xin / Wu, Hong-Ping / Zhang, Hui-Lu / Ashton, Charles / Tong, Chang / Wu, Han / Qian, Qi-Jun / Wang, Hong-Yang / Ying, Qi-Long | 2013
769
Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma
Waidmann, Oliver / Köberle, Verena / Bettinger, Dominik / Trojan, Jörg / Zeuzem, Stefan / Schultheiß, Michael / Kronenberger, Bernd / Piiper, Albrecht | 2013
780
ER stress in human hepatic cells treated with Efavirenz: Mitochondria again
Apostolova, N. / Gomez-Sucerquia, L. J. / Alegre, F. / Funes, H. A. / Victor, V. M. / Barrachina, M. D. / Blas-Garcia, A. / Esplugues, J. V. | 2013
790
Regulatory T cells inhibit Th1 cell-mediated bile duct injury in murine biliary atresia
Tucker, R. M. / Feldman, A. G. / Fenner, E. K. / Mack, C. L. | 2013
797
Gender matters: Estrogen receptor alpha (ERα) and histone deacetylase (HDAC) 1 and 2 control the gender-specific transcriptional regulation of human uridine diphosphate glucuronosyltransferases genes (UGT1A)
Kalthoff, S. / Winkler, A. / Freiberg, N. / Manns, M. P. / Strassburg, C. P. | 2013
805
ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading
Fernandez, Anna / Matias, Núria / Fucho, Raquel / Ribas, Vicente / Von Montfort, Claudia / Nuño, Natalia / Baulies, Anna / Martinez, Laura / Tarrats, Núria / Mari, Montserrat et al. | 2013
814
Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines
Sokal, Etienne M. / Paganelli, Massimiliano / Wirth, Stefan / Socha, Piotr / Vajro, Pietro / Lacaille, Florence / Kelly, Deirdre / Mieli-Vergani, Giorgina | 2013
814
Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines:Consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition
Sokal, E. M. / Paganelli, M. / Wirth, S. / Socha, P. / Vajro, P. / Lacaille, F. / Kelly, D. / Mieli-Vergani, G. | 2013
830
Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis
Frau, Maddalena / Feo, Francesco / Pascale, Rosa M. | 2013
842
The metabolomic window into hepatobiliary disease
Beyoğlu, D. / Idle, J. R. | 2013
859
From NAFLD in clinical practice to answers from guidelines
Nascimbeni, F. / Pais, R. / Bellentani, S. / Day, C. P. / Ratziu, V. / Loria, P. / Lonardo, A. | 2013
872
Immunosuppression minimization vs. complete drug withdrawal in liver transplantation
Londoño, Maria-Carlota / Rimola, Antoni / O’Grady, John / Sanchez-Fueyo, Alberto | 2013
880
Reversal of cirrhosis: An achievable goal of hepatitis B antiviral therapy
Liaw, Y. F. | 2013
882
Oncolytic immunotherapeutic virus in HCC: Can it compete with molecular therapies?
Hernandez-Gea, V. / Alsinet, C. / Llovet, J. M. | 2013
885
ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection
Asselah, T. | 2013
889
Coagulopathy in cirrhosis – The role of the platelet in hemostasis
Tapper, Elliot B. / Robson, Simon C. / Malik, Raza | 2013
891
Cannabinoid signaling and liver therapeutics
Mallat, Ariane / Teixeira-Clerc, Fatima / Lotersztajn, Sophie | 2013
897
Challenges in cancer vaccine development for hepatocellular carcinoma
Buonaguro, Luigi / Petrizzo, Annacarmen / Tagliamonte, Maria / Tornesello, Maria Lina / Buonaguro, Franco M. | 2013
904
Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation
Willson, J.S.B. / Godwin, T.D. / Wiggins, G.A.R. / Guilford, P.J. / McCall, J.L. | 2013
908
Infliximab as rescue therapy in paediatric autoimmune hepatitis
Rajanayagam, Jeremy / Lewindon, Peter J. | 2013
909
Flow cytometry makes all the difference
Pembroke, Tom / Gallimore, Awen / Godkin, Andrew | 2013
910
Reply to: “Flow cytometry makes all the difference”
Oliviero, Barbara / Mele, Dalila / Varchetta, Stefania / Mondelli, Mario U. | 2013
912
Circulating platelet derived microparticles are not increased in patients with cirrhosis
Rautou, Pierre-Emmanuel / Vion, Anne-Clémence / Valla, Dominique / Boulanger, Chantal M. | 2013
913
Reply to: “Circulating platelet derived microparticles are not increased in patients with cirrhosis”
Tapper, Elliot B. / Robson, Simon / Malik, Raza | 2013
914
Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235]
Poynard, T. / Munteanu, M. / Colombo, M. / Bruix, J. / Schiff, E. / Terg, R. / Flamm, S. / Moreno-Otero, R. / Carrilho, F. / Schmidt, W. | 2013
vii
Contents
| 2013
EASL Basic School of Hepatology, Epithelial Mesenchymal Interactions in Liver Development, Diseases and Cancer, Milan 2014
| 2013
Call for applications for the Journal of Hepatology: Editor-in-Chief 2015–2020
| 2013
Journal of Hepatology iPad edition now available
| 2013
EASL LiverTreeTM
| 2013
Editorial Board
| 2013
IFC See you in London for the International Liver CongressTM 2014
| 2013
Join EASL today, become part of our vision
| 2013
Translational Research in Chronic Viral Hepatitis: EASL Monothematic Conference, Lyon 2013
| 2013
EASL iLiver app
| 2013

Ähnliche Titel